The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA) in adults and kids ages 2 years and up, ...

Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...

Summary • Omeros Corporation’s stock jumped 72.1% to $15.06 following FDA approval of Yartemlea, its therapy for TA-TMA.• ...

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. The stock was up 78% to $15.60 on Wednesday and was briefly paused ...

Trapped in a hell he helped make, a lone hacker aboard a space station far from home sneaks and fights his way through horrible mutants and killer robots in order to take down the monstrous artificial ...

The new grading structure under the Competency-Based Education (CBE) system is going to reshape how learners transitioning to Senior School will be assessed and placed. The system, built on cumulative ...